Portage Biotech Inc. (PRTG)
USD 10.27
(-4.55%)
USD 10.27
(-4.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -18.19 Million USD | -15.37% |
| 2023 | -15.77 Million USD | -6.19% |
| 2022 | - USD | -10.32% |
| 2021 | - USD | -138.46% |
| 2020 | - USD | -111.33% |
| 2019 | -650 Thousand USD | -26.4% |
| 2018 | -2.06 Million USD | 95.54% |
| 2017 | -35.33 Million USD | -443.67% |
| 2016 | -5.00 USD | -112.83% |
| 2015 | -4.31 Million USD | -54.83% |
| 2014 | -6.62 Million USD | -126.07% |
| 2013 | -1.46 Million USD | -37.41% |
| 2012 | -2.48 Million USD | 70.92% |
| 2011 | -3.71 Million USD | -1.85% |
| 2010 | -3.29 Million USD | -584.5% |
| 2009 | -492.6 Thousand USD | -26.94% |
| 2008 | -553.14 Thousand USD | 28.78% |
| 2007 | -489.7 Thousand USD | -110.54% |
| 2006 | -2.34 Million USD | 206.14% |
| 2005 | -4.01 Million USD | -295.68% |
| 2004 | -1.04 Million USD | -390.25% |
| 2003 | -216.59 Thousand USD | 53.47% |
| 2002 | -646.19 Thousand USD | -225.34% |
| 2001 | -342.01 Thousand USD | 141.06% |
| 2000 | -942.47 Thousand USD | -209.73% |
| 1999 | -304.29 Thousand USD | 19.52% |
| 1998 | -378.11 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - USD | -9.51% |
| 2024 Q1 | -3.9 Million USD | 95.43% |
| 2024 Q4 | -3.24 Million USD | 48.92% |
| 2024 Q3 | -4.02 Million USD | -710.97% |
| 2024 Q2 | -5.91 Million USD | -20.21% |
| 2023 Q2 | -3.66 Million USD | 11.17% |
| 2023 Q4 | -3.96 Million USD | 18.41% |
| 2023 FY | - USD | -6.19% |
| 2023 Q1 | -4.12 Million USD | 1.64% |
| 2023 Q3 | -4.86 Million USD | -32.63% |
| 2022 Q2 | -3.38 Million USD | 6.85% |
| 2022 Q3 | -4.43 Million USD | -30.76% |
| 2022 Q4 | -4.19 Million USD | 5.3% |
| 2022 FY | - USD | -10.32% |
| 2022 Q1 | -3.63 Million USD | 64.54% |
| 2021 Q1 | -533 Thousand USD | 71.68% |
| 2021 Q4 | -10.25 Million USD | -1113.96% |
| 2021 FY | - USD | -138.46% |
| 2021 Q3 | -845 Thousand USD | 66.86% |
| 2021 Q2 | -2.55 Million USD | -378.42% |
| 2020 FY | - USD | -111.33% |
| 2020 Q1 | -1.84 Million USD | 34.46% |
| 2020 Q4 | -1.88 Million USD | -169.24% |
| 2020 Q3 | -699 Thousand USD | 56.12% |
| 2020 Q2 | -1.59 Million USD | 13.47% |
| 2019 Q4 | -2.8 Million USD | -885.61% |
| 2019 FY | - USD | -26.4% |
| 2019 Q3 | -285 Thousand USD | -42.5% |
| 2019 Q1 | -211 Thousand USD | 82.79% |
| 2019 Q2 | -200 Thousand USD | 5.21% |
| 2018 Q3 | -343 Thousand USD | -3.0% |
| 2018 Q1 | -325.07 Thousand USD | 99.57% |
| 2018 FY | - USD | 95.54% |
| 2018 Q2 | -333 Thousand USD | -2.44% |
| 2018 Q4 | -1.22 Million USD | -257.43% |
| 2017 Q2 | 37.38 Million USD | 849.28% |
| 2017 FY | - USD | -443.67% |
| 2017 Q4 | -76.19 Million USD | -1154.95% |
| 2017 Q3 | -6.07 Million USD | -116.24% |
| 2017 Q1 | -4.98 Million USD | -178.66% |
| 2016 Q1 | -1.03 Million USD | 28.3% |
| 2016 Q2 | -1.53 Million USD | -48.27% |
| 2016 Q4 | -1.79 Million USD | 62.94% |
| 2016 Q3 | -4.83 Million USD | -215.35% |
| 2016 FY | - USD | -112.83% |
| 2015 Q3 | -887.04 Thousand USD | 7.37% |
| 2015 Q1 | -1.03 Million USD | 47.9% |
| 2015 Q2 | -957.58 Thousand USD | 7.13% |
| 2015 FY | - USD | -54.83% |
| 2015 Q4 | -1.44 Million USD | -62.49% |
| 2014 Q2 | -347.56 Thousand USD | -94.55% |
| 2014 Q3 | -282.92 Thousand USD | 18.6% |
| 2014 Q1 | -178.64 Thousand USD | 67.7% |
| 2014 FY | - USD | -126.07% |
| 2014 Q4 | -1.97 Million USD | -599.52% |
| 2013 FY | - USD | -37.41% |
| 2013 Q4 | -553.03 Thousand USD | -284.13% |
| 2013 Q2 | -1.76 Million USD | -748.03% |
| 2013 Q1 | -207.78 Thousand USD | -154.23% |
| 2013 Q3 | 300.35 Thousand USD | 117.05% |
| 2012 FY | - USD | 70.92% |
| 2012 Q4 | 383.17 Thousand USD | 217.13% |
| 2012 Q3 | -327.12 Thousand USD | 25.73% |
| 2012 Q1 | -533.37 Thousand USD | 2.14% |
| 2012 Q2 | -440.45 Thousand USD | 17.42% |
| 2011 Q1 | -511.35 Thousand USD | 68.99% |
| 2011 Q3 | -1.09 Million USD | 19.57% |
| 2011 FY | - USD | -1.85% |
| 2011 Q4 | -545.05 Thousand USD | 50.26% |
| 2011 Q2 | -1.36 Million USD | -166.46% |
| 2010 FY | - USD | -584.5% |
| 2010 Q1 | -158.82 Thousand USD | -7.33% |
| 2010 Q2 | -713.1 Thousand USD | -348.98% |
| 2010 Q3 | -704.21 Thousand USD | 1.25% |
| 2010 Q4 | -1.64 Million USD | -134.13% |
| 2009 Q3 | -225.75 Thousand USD | -22.63% |
| 2009 Q2 | -184.09 Thousand USD | -2378.07% |
| 2009 Q1 | 8081.16 USD | 112.49% |
| 2009 Q4 | -147.98 Thousand USD | 34.45% |
| 2009 FY | - USD | -26.94% |
| 2008 Q2 | -39.47 Thousand USD | 73.32% |
| 2008 Q3 | -139.98 Thousand USD | -254.58% |
| 2008 Q1 | -147.96 Thousand USD | -532.73% |
| 2008 Q4 | -64.68 Thousand USD | 53.79% |
| 2008 FY | - USD | 28.78% |
| 2007 Q1 | 21.27 Thousand USD | -98.33% |
| 2007 Q3 | -302.51 Thousand USD | -29.37% |
| 2007 Q2 | -233.82 Thousand USD | -1198.92% |
| 2007 Q4 | 34.19 Thousand USD | 111.3% |
| 2007 FY | - USD | -110.54% |
| 2006 Q1 | -1.03 Million USD | 71.92% |
| 2006 Q3 | -790.66 Thousand USD | -116.05% |
| 2006 FY | - USD | 206.14% |
| 2006 Q2 | 4.92 Million USD | 576.15% |
| 2006 Q4 | 1.27 Million USD | 260.96% |
| 2005 Q3 | -228.57 Thousand USD | 2.23% |
| 2005 FY | - USD | -295.68% |
| 2005 Q4 | -3.68 Million USD | -1512.18% |
| 2005 Q2 | -233.79 Thousand USD | 13.33% |
| 2005 Q1 | -269.74 Thousand USD | 70.46% |
| 2004 Q3 | -65.41 Thousand USD | 17.01% |
| 2004 FY | - USD | -390.25% |
| 2004 Q2 | -78.81 Thousand USD | -121.66% |
| 2004 Q4 | -912.99 Thousand USD | -1295.8% |
| 2004 Q1 | -35.55 Thousand USD | -0.48% |
| 2003 Q1 | -45.67 Thousand USD | 80.73% |
| 2003 Q4 | -35.38 Thousand USD | 57.82% |
| 2003 Q2 | -52.89 Thousand USD | -7.22% |
| 2003 FY | - USD | 53.47% |
| 2003 Q3 | -83.88 Thousand USD | -58.58% |
| 2002 Q2 | -47.58 Thousand USD | -10.23% |
| 2002 Q3 | -315.26 Thousand USD | -185.66% |
| 2002 FY | - USD | -225.34% |
| 2002 Q4 | -243.55 Thousand USD | -81.79% |
| 2002 Q1 | -42.64 Thousand USD | -10.88% |
| 2001 Q3 | 556.98 Thousand USD | 0.0% |
| 2001 FY | - USD | 141.06% |
| 2001 Q4 | 42.34 Thousand USD | -107.24% |
| 2000 FY | - USD | -209.73% |
| 1999 FY | - USD | 19.52% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -71.156% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -561.402% |
| XOMA Corporation | -39.36 Million USD | 53.765% |
| Mesoblast Limited | -61.33 Million USD | 70.327% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 23.324% |
| Aptorum Group Limited | -9.59 Million USD | -89.593% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -61.048% |
| HilleVax, Inc. | -132.46 Million USD | 86.261% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 92.309% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 59.045% |
| Precision BioSciences, Inc. | -32.04 Million USD | 43.203% |
| Dyadic International, Inc. | -8.22 Million USD | -121.137% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -80.438% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 86.046% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -6153.952% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 37.798% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 73.625% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 90.385% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 85.144% |
| IGM Biosciences, Inc. | -253.35 Million USD | 92.817% |
| Opthea Limited | -200.01 Million USD | 90.901% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 67.985% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 64.014% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 84.048% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 117.89% |
| NextCure, Inc. | -59.03 Million USD | 69.175% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 8.605% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 69.004% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 15.507% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 24.692% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 88.423% |
| Senti Biosciences, Inc. | -61.33 Million USD | 70.329% |
| Apollomics, Inc. | -171.74 Million USD | 89.404% |
| PureTech Health plc | -11.62 Million USD | -56.524% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 914.273% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 75.675% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 87.291% |
| ChromaDex Corporation | -3.89 Million USD | -367.36% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 4341.806% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -164.983% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 79.184% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 7461.579% |
| Gritstone bio, Inc. | -126.86 Million USD | 85.655% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -708.945% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 89.433% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 88.998% |
| Fortress Biotech, Inc. | -133.64 Million USD | 86.382% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 65.101% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 41.956% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 91.92% |
| Celcuity Inc. | -58.3 Million USD | 68.789% |
| ContextLogic Inc. | -324 Million USD | 94.383% |
| GH Research PLC | -41.15 Million USD | 55.777% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 76.47% |
| Cassava Sciences, Inc. | -95.68 Million USD | 80.981% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 28.412% |
| ImmuCell Corporation | -2.5 Million USD | -626.775% |
| Amarin Corporation plc | -50.9 Million USD | 64.247% |
| TG Therapeutics, Inc. | 26.1 Million USD | 169.728% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 83.008% |
| Acelyrin, Inc. | -381.52 Million USD | 95.23% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -279.821% |
| Seer, Inc. | -97.88 Million USD | 81.408% |
| Novavax, Inc. | -487.39 Million USD | 96.266% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 88.558% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 101.256% |
| AnaptysBio, Inc. | -143.16 Million USD | 87.288% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 35.718% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 76.927% |
| AbCellera Biologics Inc. | -192.15 Million USD | 90.529% |
| CorMedix Inc. | -48.88 Million USD | 62.773% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 92.258% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -54.33% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.391% |
| Aptose Biosciences Inc. | -52.26 Million USD | 65.181% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 83.109% |
| Soligenix, Inc. | -7.85 Million USD | -131.75% |
| Century Therapeutics, Inc. | -121.2 Million USD | 84.985% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 89.64% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -1.255% |
| Kura Oncology, Inc. | -164.95 Million USD | 88.967% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 85.539% |
| Ardelyx, Inc. | -55.35 Million USD | 67.123% |
| Ainos, Inc. | -8.77 Million USD | -107.441% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 77.279% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -1800.205% |
| Prothena Corporation plc | -190.1 Million USD | 90.427% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -322.349% |
| Autolus Therapeutics plc | -156.77 Million USD | 88.391% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 78.503% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 85.804% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 8.704% |
| Celularity Inc. | -183.94 Million USD | 90.106% |
| Rallybio Corporation | -72.37 Million USD | 74.854% |
| GRI Bio, Inc. | -10.89 Million USD | -66.994% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -303.015% |
| Omeros Corporation | -163.61 Million USD | 88.877% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 82.466% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 52.275% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -18.708% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -15.599% |
| Humacyte, Inc. | -96.45 Million USD | 81.133% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 93.158% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 90.616% |
| Immunocore Holdings plc | -59.64 Million USD | 69.49% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 6.055% |
| Verastem, Inc. | -83.16 Million USD | 78.117% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 88.498% |
| Histogen Inc. | -10.5 Million USD | -73.274% |
| Surrozen, Inc. | -41.13 Million USD | 55.754% |
| Blueprint Medicines Corporation | -474.61 Million USD | 96.165% |
| Organovo Holdings, Inc. | -14.8 Million USD | -22.916% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 567577.393% |
| IO Biotech, Inc. | -91.22 Million USD | 80.051% |
| MEI Pharma, Inc. | 26.38 Million USD | 168.988% |
| GT Biopharma, Inc. | 5.97 Million USD | 404.382% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 89.041% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 63.054% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 75.15% |
| Summit Therapeutics Inc. | 1 Million USD | 1918.082% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 41.111% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 85.498% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -20.883% |
| Turnstone Biologics Corp. | -56.23 Million USD | 67.637% |
| Pulmatrix, Inc. | -12.64 Million USD | -43.911% |
| Synaptogenix, Inc. | -8.3 Million USD | -119.067% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -18.645% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 71.134% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 79.428% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 96.406% |
| Cytokinetics, Incorporated | -456.68 Million USD | 96.015% |
| Exelixis, Inc. | 196.6 Million USD | 109.257% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 87.13% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 96.325% |
| Evogene Ltd. | -23.2 Million USD | 21.57% |
| Replimune Group, Inc. | -230.19 Million USD | 92.094% |
| PDS Biotechnology Corporation | -40.08 Million USD | 54.599% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -11783.199% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 71.995% |
| ESSA Pharma Inc. | -26.45 Million USD | 31.209% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -354.981% |
| BioLineRx Ltd. | -57.06 Million USD | 68.106% |
| Avid Bioservices, Inc. | -11.48 Million USD | -58.514% |
| Insmed Incorporated | -654.73 Million USD | 97.22% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 43.922% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 93.394% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 40.797% |
| MediWound Ltd. | -4.89 Million USD | -271.94% |
| MiMedx Group, Inc. | 40.51 Million USD | 144.917% |
| OmniAb, Inc. | -49.73 Million USD | 63.405% |
| Alector, Inc. | -142.89 Million USD | 87.264% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 78.698% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 94.491% |
| Mereo BioPharma Group plc | -26.05 Million USD | 30.154% |
| Zai Lab Limited | -366.57 Million USD | 95.035% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 93.738% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 92.085% |
| Aura Biosciences, Inc. | -83.69 Million USD | 78.256% |
| Immunic, Inc. | -99.11 Million USD | 81.638% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 92.205% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 86.178% |
| Veracyte, Inc. | -49.4 Million USD | 63.167% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -157.633% |
| FibroGen, Inc. | -261.4 Million USD | 93.038% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -63.352% |
| Allakos Inc. | -189.91 Million USD | 90.417% |
| scPharmaceuticals Inc. | -46.06 Million USD | 60.489% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 83.225% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 116.801% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -159.936% |
| NLS Pharmaceutics AG | -11.79 Million USD | -54.286% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 2.767% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 145.623% |
| Precigen, Inc. | -89.22 Million USD | 79.603% |
| Fortrea Holdings Inc. | 167.3 Million USD | 110.878% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 86.447% |
| Incyte Corporation | 919.42 Million USD | 101.979% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -84.072% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 84.531% |
| XBiotech Inc. | -35.76 Million USD | 49.116% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 78.287% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 71.995% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 24.523% |
| CRISPR Therapeutics AG | -202.7 Million USD | 91.022% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 87.756% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -33.297% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 72.109% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 82.577% |
| Agenus Inc. | -145.92 Million USD | 87.528% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -47.36% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 29.11% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 55.468% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 96.476% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 67.514% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -184.866% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 84.356% |
| UroGen Pharma Ltd. | -63.83 Million USD | 71.489% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 17.91% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 73.203% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -229.361% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 28.685% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 28.328% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 83.795% |
| Chimerix, Inc. | -92.97 Million USD | 80.426% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 77.869% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 68.281% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -1175.74% |
| Pluri Inc. | -20.22 Million USD | 10.017% |
| Cue Biopharma, Inc. | -46.05 Million USD | 60.482% |
| MeiraGTx Holdings plc | -57.05 Million USD | 68.101% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -27.447% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -118.266% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 25.307% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -2.186% |
| CalciMedica, Inc. | -34.18 Million USD | 46.769% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 89.196% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 92.789% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 44.795% |
| NLS Pharmaceutics AG | -11.79 Million USD | -54.286% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 82.019% |
| Nutriband Inc. | -5.12 Million USD | -255.326% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 57.943% |
| Vor Biopharma Inc. | -114.37 Million USD | 84.088% |
| Roivant Sciences Ltd. | -996.51 Million USD | 98.174% |
| ProKidney Corp. | -147.66 Million USD | 87.676% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 71.8% |
| Daré Bioscience, Inc. | -30.7 Million USD | 40.723% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 96.782% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -153.999% |
| Bicycle Therapeutics plc | -183.4 Million USD | 90.077% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 83.716% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -8909.406% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 95.773% |
| Atai Life Sciences N.V. | -36.31 Million USD | 49.88% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 77.113% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 77.619% |
| MediciNova, Inc. | -9.87 Million USD | -84.201% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 85.55% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -1089.321% |
| GeoVax Labs, Inc. | -26.66 Million USD | 31.759% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 79.855% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 91.911% |
| Biomea Fusion, Inc. | -124.62 Million USD | 85.396% |
| RenovoRx, Inc. | -11.39 Million USD | -59.781% |
| Erasca, Inc. | -121.31 Million USD | 84.998% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 90.439% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 39.387% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 83.01% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 20.372% |
| bluebird bio, Inc. | -167.16 Million USD | 89.113% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 91.244% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 20.047% |
| Imunon, Inc. | -19.87 Million USD | 8.448% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 105.865% |
| BioAtla, Inc. | -122.24 Million USD | 85.112% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 93.94% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 56.091% |
| DBV Technologies S.A. | -85.98 Million USD | 78.834% |
| Fortress Biotech, Inc. | -133.64 Million USD | 86.382% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 92.206% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 81.664% |
| aTyr Pharma, Inc. | -52.17 Million USD | 65.121% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 92.241% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -126.291% |
| Galecto, Inc. | -37.51 Million USD | 51.494% |
| Akari Therapeutics, Plc | -16.8 Million USD | -8.314% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 9744.102% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 104.027% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 88.867% |
| Entera Bio Ltd. | -8.8 Million USD | -106.713% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 94.422% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 45.489% |
| Xencor, Inc. | -125.87 Million USD | 85.542% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 64.468% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 61.578% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 9.717% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -66.322% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -184.866% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -1089.321% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 82.599% |
| OncoCyte Corporation | -23.12 Million USD | 21.295% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -58.848% |
| Purple Biotech Ltd. | -22.22 Million USD | 18.115% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -183.916% |
| Onconetix, Inc. | -36.7 Million USD | 50.421% |
| MacroGenics, Inc. | 2.01 Million USD | 1002.281% |
| Tharimmune, Inc. | -9.3 Million USD | -95.634% |
| Genprex, Inc. | -31.06 Million USD | 41.408% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 78.331% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 90.295% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -82.574% |
| Prime Medicine, Inc. | -193.75 Million USD | 90.607% |
| Aditxt, Inc. | -25.45 Million USD | 28.514% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -2282.068% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 12159.985% |
| OKYO Pharma Limited | -15.74 Thousand USD | -115479.514% |
| Savara Inc. | -59.13 Million USD | 69.224% |
| Curis, Inc. | -45.13 Million USD | 59.682% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -19.8% |
| Adagene Inc. | -14.95 Million USD | -21.726% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 31.926% |
| BeiGene, Ltd. | -1.12 Billion USD | 98.382% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 91.195% |
| GlycoMimetics, Inc. | -39.12 Million USD | 53.481% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 102.555% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -304.534% |
| SciSparc Ltd. | -5.28 Million USD | -244.548% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -304.534% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 57.288% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -19014.99% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 16.101% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -222.22% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 91.998% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 69.593% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 92.953% |
| ADMA Biologics, Inc. | 5.12 Million USD | 455.449% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -7.173% |
| Clene Inc. | -43.24 Million USD | 57.913% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 86.91% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 91.16% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 62.458% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 93.925% |
| Adicet Bio, Inc. | -136.53 Million USD | 86.671% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 177.203% |
| Absci Corporation | -95.45 Million USD | 80.935% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -148.957% |
| Quantum-Si incorporated | -91.8 Million USD | 80.176% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 114.392% |
| Surrozen, Inc. | -41.13 Million USD | 55.754% |
| Generation Bio Co. | -133.3 Million USD | 86.347% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 78.081% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 83.828% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 78.844% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 74.376% |
| Invivyd, Inc. | -196.61 Million USD | 90.744% |
| Cingulate Inc. | -22.95 Million USD | 20.709% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 95.136% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -96.22% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -121.228% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 167.021% |
| Jaguar Health, Inc. | -33.13 Million USD | 45.07% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -76.947% |
| 2seventy bio, Inc. | -206.41 Million USD | 91.183% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 21.073% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 82.204% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 73.169% |
| Capricor Therapeutics, Inc. | -23 Million USD | 20.905% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 50.451% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 470.632% |
| Kronos Bio, Inc. | -121.83 Million USD | 85.062% |
| Innoviva, Inc. | 248.96 Million USD | 107.31% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 75.52% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -5569.47% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 88.511% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 97.341% |
| Evaxion Biotech A/S | -21.4 Million USD | 14.97% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 72.598% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 91.639% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 77.135% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -143.922% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 51.187% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 68.822% |
| Clearmind Medicine Inc. | -8.71 Million USD | -108.928% |
| AlloVir, Inc. | -190.14 Million USD | 90.429% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 83.417% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 120.964% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -645.429% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 81.95% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 88.041% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 3540.265% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 91.784% |
| ImmunityBio, Inc. | -436.18 Million USD | 95.828% |
| Korro Bio, Inc. | -80.9 Million USD | 77.505% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 85.095% |
| Kineta, Inc. | -15.71 Million USD | -15.814% |
| Lantern Pharma Inc. | -15.78 Million USD | -15.281% |
| BioVie Inc. | -31.95 Million USD | 43.039% |
| Codexis, Inc. | -49.28 Million USD | 63.072% |
| Celularity Inc. | -183.94 Million USD | 90.106% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| Virax Biolabs Group Limited | -6.6 Million USD | -175.361% |
| Kodiak Sciences Inc. | -259.02 Million USD | 92.974% |
| Cibus, Inc. | -314.58 Million USD | 94.215% |
| Annexon, Inc. | -141.57 Million USD | 87.145% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 71.651% |
| Moderna, Inc. | -3.28 Billion USD | 99.446% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 92.088% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 83.837% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 34.899% |
| Immix Biopharma, Inc. | -16.13 Million USD | -12.788% |
| Eyenovia, Inc. | -24.1 Million USD | 24.504% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 140.637% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 86.725% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 69.044% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -5516.975% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 75.341% |
| Alkermes plc | 495.04 Million USD | 103.676% |
| Arcellx, Inc. | -64.14 Million USD | 71.628% |
| Moolec Science SA | -52.07 Million USD | 65.053% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 59.57% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 54.972% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 85.261% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 41.069% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 84.783% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 62.455% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -95.179% |
| Humacyte, Inc. | -96.45 Million USD | 81.133% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 64.735% |
| Geron Corporation | -174.78 Million USD | 89.588% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 70.74% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 549.136% |
| Royalty Pharma plc | 1.88 Billion USD | 100.964% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 12.255% |
| Notable Labs, Ltd. | -14.4 Million USD | -26.382% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 89.042% |
| Structure Therapeutics Inc. | -102.45 Million USD | 82.238% |
| IN8bio, Inc. | -28.5 Million USD | 36.153% |
| 89bio, Inc. | -134.46 Million USD | 86.465% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 5.744% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 82.16% |
| Acasti Pharma Inc. | -11.3 Million USD | -61.039% |
| Genelux Corporation | -24.16 Million USD | 24.689% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 46.157% |
| Liquidia Corporation | -70.05 Million USD | 74.02% |
| Mustang Bio, Inc. | -48.06 Million USD | 62.135% |
| Immunovant, Inc. | -269.97 Million USD | 93.259% |
| Vericel Corporation | 2.86 Million USD | 735.44% |
| Quantum-Si incorporated | -91.8 Million USD | 80.176% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 74.363% |
| XOMA Corporation | -39.36 Million USD | 53.765% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 73.017% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 18.219% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -18.708% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 47.411% |
| Vaxcyte, Inc. | -464.88 Million USD | 96.085% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 91.355% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -148.957% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -14.603% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 36.756% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 37.165% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 89.197% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 50.853% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 35.508% |
| PepGen Inc. | -83.58 Million USD | 78.226% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 38.317% |
| United Therapeutics Corporation | 1.38 Billion USD | 101.312% |
| Solid Biosciences Inc. | -93.43 Million USD | 80.522% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -281.392% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -5516.975% |
| Immuneering Corporation | -58.06 Million USD | 68.655% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 567577.393% |
| Silo Pharma, Inc. | -3.62 Million USD | -401.873% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -197.537% |
| Belite Bio, Inc | -31.52 Million USD | 42.279% |
| Pharming Group N.V. | 9.87 Million USD | 284.256% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 24.523% |
| Bionomics Limited | -9.83 Million USD | -85.006% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 76.814% |
| uniQure N.V. | -253.1 Million USD | 92.81% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 9.723% |
| GeoVax Labs, Inc. | -26.66 Million USD | 31.759% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 85.947% |
| Altimmune, Inc. | -87.93 Million USD | 79.304% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -126.061% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 47.411% |
| Peak Bio, Inc. | -1356.23 USD | -1341781.539% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -63.352% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -14.452% |
| Benitec Biopharma Inc. | -22.49 Million USD | 19.08% |
| Zura Bio Limited | -60.56 Million USD | 69.95% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 80.235% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -141142.96% |
| Compugen Ltd. | -12.51 Million USD | -45.406% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -326.172% |
| argenx SE | -216.02 Million USD | 91.575% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 62.552% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 20.518% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 92.489% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 36.24% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 95.21% |
| PolyPid Ltd. | -20.26 Million USD | 10.186% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -16.563% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -43.378% |
| Forte Biosciences, Inc. | -32.47 Million USD | 43.963% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 62.222% |
| Instil Bio, Inc. | -146.12 Million USD | 87.545% |
| Elevation Oncology, Inc. | -41.46 Million USD | 56.112% |
| Immunome, Inc. | -28.27 Million USD | 35.627% |
| Verona Pharma plc | -52.46 Million USD | 65.314% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -6.179% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 80.797% |
| Shattuck Labs, Inc. | -87.61 Million USD | 79.228% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 85.113% |
| Design Therapeutics, Inc. | -66.32 Million USD | 72.561% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 77.528% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 51.791% |
| Achilles Therapeutics plc | -70.44 Million USD | 74.165% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 63.998% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 72.12% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 66.367% |
| Beam Therapeutics Inc. | -156.47 Million USD | 88.369% |
| Moolec Science SA | -52.07 Million USD | 65.053% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 67.934% |
| AEON Biopharma, Inc. | -48.36 Million USD | 62.368% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 72.158% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 77.788% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 95.742% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 82.7% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 86.043% |
| Athira Pharma, Inc. | -116.7 Million USD | 84.406% |
| HCW Biologics Inc. | -23.57 Million USD | 22.807% |
| XOMA Corporation | -39.36 Million USD | 53.765% |
| NeurAxis, Inc. | -6.66 Million USD | -173.074% |
| Lumos Pharma, Inc. | -36.57 Million USD | 50.235% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 80.797% |
| 180 Life Sciences Corp. | -22.13 Million USD | 17.778% |
| Nektar Therapeutics | -243.1 Million USD | 92.514% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 36.24% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 412.202% |
| Arvinas, Inc. | -394.8 Million USD | 95.39% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -645.429% |
| Palisade Bio, Inc. | -12.28 Million USD | -48.188% |
| Nutriband Inc. | -5.12 Million USD | -255.326% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 9744.102% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 67.169% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 59.893% |
| Merus N.V. | -149.2 Million USD | 87.803% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 80.534% |
| Neurogene Inc. | -52.28 Million USD | 65.193% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 86.666% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -116.758% |
| CervoMed Inc. | -2.17 Million USD | -737.94% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 80.435% |
| Sesen Bio, Inc. | -50.84 Million USD | 64.203% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 41.782% |
| Rezolute, Inc. | -68.42 Million USD | 73.402% |
| Clene Inc. | -43.24 Million USD | 57.913% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -18.005% |
| BeyondSpring Inc. | -21.54 Million USD | 15.511% |
| Synlogic, Inc. | -55.16 Million USD | 67.007% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -50.617% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -71.011% |
| Peak Bio, Inc. | -1356.23 USD | -1341781.539% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 43.943% |
| Krystal Biotech, Inc. | 17.9 Million USD | 201.648% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 84.632% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 94.668% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -295.078% |
| MannKind Corporation | 15.12 Million USD | 220.292% |
| Ikena Oncology, Inc. | -74.39 Million USD | 75.538% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -44.517% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 189.531% |
| Gossamer Bio, Inc. | -172.15 Million USD | 89.429% |
| CohBar, Inc. | -12.06 Million USD | -50.832% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 28.657% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 39.387% |
| Legend Biotech Corporation | -477.87 Million USD | 96.192% |
| Mural Oncology plc | -192.72 Million USD | 90.557% |
| Disc Medicine, Inc. | -91.02 Million USD | 80.007% |
| Champions Oncology, Inc. | -5.05 Million USD | -260.091% |
| REGENXBIO Inc. | -239.46 Million USD | 92.4% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -69.796% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 67.36% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 53.057% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 83.867% |
| Vaxart, Inc. | -74.72 Million USD | 75.645% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 48.31% |
| Cellectis S.A. | -98.09 Million USD | 81.448% |
| Longeveron Inc. | -20.06 Million USD | 9.277% |
| Repare Therapeutics Inc. | -114.27 Million USD | 84.074% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 95.856% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 75.674% |
| Revolution Medicines, Inc. | -430.58 Million USD | 95.773% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -189.378% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 40.891% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 75.601% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 471.181% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -65.974% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.395% |
| Denali Therapeutics Inc. | -179.97 Million USD | 89.888% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -19014.99% |
| Veru Inc. | -89.97 Million USD | 79.773% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 32.29% |
| Cingulate Inc. | -22.95 Million USD | 20.709% |
| Passage Bio, Inc. | -98.34 Million USD | 81.494% |
| Context Therapeutics Inc. | -25.06 Million USD | 27.38% |
| Exicure, Inc. | -15.53 Million USD | -17.118% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 91.168% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 50.782% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -205.219% |
| Nuvalent, Inc. | -149.49 Million USD | 87.826% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -123.783% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 78.812% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 39.694% |
| OmniAb, Inc. | -49.73 Million USD | 63.405% |
| Anew Medical, Inc. | -1.3 Million USD | -1299.019% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -47.193% |
| Lipocine Inc. | -16.32 Million USD | -11.495% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 72.703% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 75.507% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 52.275% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 53.353% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 17.96% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 96.661% |
| Ocugen, Inc. | -64.82 Million USD | 71.927% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 80.34% |
| Q32 Bio Inc. | -86.5 Million USD | 78.961% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -7.515% |
| Alumis Inc. Common Stock | -156.89 Million USD | 88.4% |
| Equillium, Inc. | -12.13 Million USD | -49.934% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 68.876% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -130.269% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 3.51% |
| Dominari Holdings Inc. | -22.44 Million USD | 18.899% |
| Edesa Biotech, Inc. | -8.19 Million USD | -122.206% |
| vTv Therapeutics Inc. | -25.41 Million USD | 28.384% |
| Bio-Techne Corporation | 326.66 Million USD | 105.571% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 95.271% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 108.41% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 86.119% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 51.38% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 87.956% |
| Nkarta, Inc. | -120.48 Million USD | 84.895% |
| BioCardia, Inc. | -11.56 Million USD | -57.431% |
| Iterum Therapeutics plc | -34.58 Million USD | 47.371% |